Degron Therapeutics is at the cutting edge of discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader (MGD) drugs. Degron has assembled a team of world-class scientific leaders and industry veterans, bringing its in-depth knowledge in the MGD space to the identification and validation of new MGD targets, particularly those disease drivers but undruggable or insufficiently drugged by other modalities, and to the discovery of novel selective MGD compounds to address unmet medical needs in all therapeutic areas.

MGDs have been discovered serendipitously in the past. Due to the complexity of ternary structure formed by E3 ligase-MGD-Target, rational design of MGD for a neo-target has been extremely challenging.

Differentiated GlueXplorerTM MGD discovery platform enabled by:
- Proprietary and structurally differentiated glue library with 10,000 compounds
- Multiple complementary screening and validation platforms
- Large data sets for AI/ML

Robust and differentiated pipeline of First-in-Class MGDs for important disease target